Your browser is no longer supported. Please, upgrade your browser.
NYMX Nymox Pharmaceutical Corporation daily Stock Chart
NYMX [NASD]
Nymox Pharmaceutical Corporation
Index- P/E- EPS (ttm)-0.26 Insider Own5.50% Shs Outstand59.12M Perf Week0.96%
Market Cap247.71M Forward P/E- EPS next Y- Insider Trans2.46% Shs Float32.17M Perf Month6.08%
Income-13.40M PEG- EPS next Q- Inst Own6.40% Short Float3.56% Perf Quarter33.87%
Sales0.20M P/S1238.56 EPS this Y10.20% Inst Trans1.64% Short Ratio6.07 Perf Half Y5.54%
Book/sh-0.02 P/B- EPS next Y- ROA-924.30% Target Price10.25 Perf Year-9.89%
Cash/sh0.02 P/C275.24 EPS next 5Y- ROE- 52W Range3.00 - 5.10 Perf YTD26.97%
Dividend- P/FCF- EPS past 5Y-2.10% ROI1018.10% 52W High-17.84% Beta0.73
Dividend %- Quick Ratio0.40 Sales past 5Y-40.80% Gross Margin33.50% 52W Low39.67% ATR0.22
Employees2 Current Ratio0.40 Sales Q/Q158.30% Oper. Margin- RSI (14)58.18 Volatility4.74% 5.93%
OptionableYes Debt/Eq- EPS Q/Q-2.30% Profit Margin- Rel Volume0.71 Prev Close4.18
ShortableYes LT Debt/Eq- EarningsMay 14 Payout- Avg Volume188.85K Price4.19
Recom- SMA200.83% SMA5012.48% SMA20014.18% Volume133,945 Change0.24%
Feb-15-11Initiated BioLogic Equity Research Sell
Apr-13-18 05:19PM  Should You Worry About Nymox Pharmaceutical Corporations (NASDAQ:NYMX) CEO Pay? Simply Wall St.
Apr-12-18 09:45AM  Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors GlobeNewswire
Apr-10-18 10:00AM  New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology GlobeNewswire
Mar-19-18 10:46AM  Should You Have Nymox Pharmaceutical Corporations (NASDAQ:NYMX) In Your Portfolio? Simply Wall St.
Mar-01-18 09:30AM  Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3 GlobeNewswire
Feb-27-18 07:27PM  Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Heres What Its Recent Performance Looks Like Simply Wall St.
Feb-05-18 11:15AM  Nymox Announces US NDA for Fexapotide for BPH GlobeNewswire
Jan-30-18 09:30AM  Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology GlobeNewswire
Jan-22-18 11:30AM  Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men GlobeNewswire +13.10%
Dec-22-17 11:46AM  ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017 Capital Cube
Dec-11-17 02:04PM  ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017 Capital Cube
Nov-30-17 02:12PM  ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017 Capital Cube
Nov-29-17 07:45AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 11:00AM  Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL GlobeNewswire
Nov-16-17 11:10AM  Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale GlobeNewswire
Nov-10-17 10:30AM  Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15 GlobeNewswire
Nov-07-17 11:15AM  Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana GlobeNewswire
Oct-26-17 08:40PM  Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio? Simply Wall St.
12:15PM  Nymox Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6 GlobeNewswire
Oct-13-17 09:37AM  Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah GlobeNewswire
Oct-10-17 10:00AM  Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12 GlobeNewswire
Sep-25-17 10:30AM  Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting GlobeNewswire
Sep-14-17 12:40PM  Nymox Application Validated: GlobeNewswire +5.24%
10:00AM  Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5 GlobeNewswire
Sep-12-17 12:13AM  ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017 Capital Cube
Sep-11-17 12:15PM  AUA Meeting in Florida September 16 Postponed Due to Hurricane GlobeNewswire
Aug-31-17 07:47PM  ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017 Capital Cube
Aug-24-17 10:42AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-09-17 10:30AM  Nymox Announces Private Placements of $3 Million GlobeNewswire
Aug-07-17 10:00AM  Nymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September GlobeNewswire
Aug-03-17 08:58PM  ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017 Capital Cube
Jul-04-17 03:16PM  ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017 Capital Cube
May-31-17 10:00AM  Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials GlobeNewswire +9.97%
May-24-17 10:01AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-16-17 05:02AM  Nymox reports 1Q loss Associated Press
May-10-17 11:15AM  NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT GlobeNewswire
May-08-17 11:00AM  NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT GlobeNewswire +6.92%
May-03-17 09:30AM  NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe GlobeNewswire +16.48%
Apr-05-17 08:47AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 Capital Cube +6.10%
08:47AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
Mar-30-17 09:30AM  Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments Accesswire
Mar-29-17 10:45AM  Nymox Provides Update on Fexapotide Development GlobeNewswire +11.56%
Nov-29-16 09:45AM  Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy GlobeNewswire
Oct-12-16 10:10AM  Company News for October 12, 2016 Zacks -8.15%
10:10AM  Company News for October 12, 2016
Oct-11-16 12:05PM  Nymox Wins Big on Late-Stage Trial 24/7 Wall St. +13.23%
12:05PM  Nymox Wins Big on Late-Stage Trial
10:00AM  Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment GlobeNewswire
Aug-29-16 10:30AM  Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show GlobeNewswire +5.90%
Aug-26-16 02:23PM  Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype TheStreet.com -23.72%
02:23PM  Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype
Aug-25-16 01:22PM  Nymox Pharmaceutical Corporation (NYMX) Has More Upside Potential, Even After Gains Insider Monkey +9.89%
01:22PM  Nymox Pharmaceutical Corporation (NYMX) Has More Upside Potential, Even After Gains at Insider Monkey
Aug-24-16 06:02PM  Why Nymox Pharma (NYMX) Closed the Day Up 83% Zacks +83.13%
06:02PM  Why Nymox Pharma (NYMX) Closed the Day Up 83%
02:40PM  Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success TheStreet.com
02:40PM  Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
12:19PM  Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery GlobeNewswire
Aug-22-16 10:15AM  Nymox reports 2Q loss
Aug-17-16 10:00AM  Nymox Announces Private Placements of $2.24 Million GlobeNewswire +24.38%
Aug-11-16 02:16PM  Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress +18.92%
01:05PM  5 Biohealth Stocks Rising 10% or More on News at 24/7 Wall St.
10:28AM  Nymox Announces Prostate Drug Progress GlobeNewswire
10:18AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX) Accesswire
05:00AM  Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company PR Newswire
Aug-10-16 10:25PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm Business Wire -40.51%
04:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX PR Newswire
03:59PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX) PR Newswire
12:36PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pharmaceutical Corporation Business Wire
Jun-23-16 08:51AM  Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data -7.62%
Jun-22-16 02:41PM  Heres Why These Five Stocks Are on the Move Today at Insider Monkey +35.19%
11:54AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016
11:35AM  Why Nymox Pharmaceutical Took Off at 24/7 Wall St.
09:46AM  Nymox stock halted ahead of release of positive prostate cancer-prevention results at MarketWatch
09:30AM  Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer GlobeNewswire
May-16-16 06:11PM  Nymox reports 1Q loss
Apr-18-16 01:20PM  Nymox Pharmaceutical Corporation (NYMX) and 2 Banks Witness Notable Insider Buying at Insider Monkey
Apr-12-16 09:50AM  Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2015 By the Numbers
Apr-06-16 01:04PM  NYMOX PHARMACEUTICAL CORP Financials
Feb-09-16 10:00AM  Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study GlobeNewswire
Feb-04-16 11:15AM  Nymox Announces Additional $2.1 Million Equity Financing GlobeNewswire
Dec-31-15 04:45PM  Nymox Files Current Financial Statements GlobeNewswire
Dec-17-15 09:00AM  Nymox Provides Update From Shareholders Annual General Meeting December 16 GlobeNewswire
Dec-09-15 01:00PM  5 Stocks Insiders Love Right Now at TheStreet
Nov-23-15 08:40AM  Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical Accesswire
Oct-29-15 10:31AM  Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer GlobeNewswire
Oct-08-15 11:00AM  Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments GlobeNewswire
Aug-11-15 01:48PM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Aug-04-15 11:45AM  Nymox Announces Change of Company's Domicile and Head Office GlobeNewswire
Jul-30-15 11:15AM  Nymox Announces Appointment of James G. Robinson to Board of Directors GlobeNewswire
Jul-28-15 12:44PM  Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results at TheStreet
12:00PM  Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online GlobeNewswire
12:36AM  Nymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results at Insider Monkey
Jul-27-15 04:15PM  Can Nymox Sustain This Massive Rally? at 24/7 Wall St.
12:36PM  Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More
09:30AM  Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207). GlobeNewswire
Jul-16-15 06:04PM  Nymox Appoints Cutler & Co. as Auditor GlobeNewswire
Jul-13-15 01:15PM  Nymox Announces Appointment of Erik Danielsen as CFO GlobeNewswire
Jun-16-15 12:12PM  Nymox Announces $850,000 Financing GlobeNewswire
May-15-15 05:32PM  Nymox Reports First Quarter 2015 Financial Results GlobeNewswire
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robinson James GeorgeDirectorMar 26Buy3.938,00031,4343,160,550Mar 27 04:10 PM
Robinson James GeorgeDirectorMar 20Buy4.028,00032,1603,152,550Mar 22 05:55 PM
Robinson James GeorgeDirectorMar 15Buy3.588,00028,6723,144,550Mar 16 10:49 AM
Robinson James GeorgeDirectorMar 09Buy3.488,00027,8643,136,550Mar 12 02:05 PM
Robinson James GeorgeDirectorFeb 21Buy3.236,00019,3733,128,550Feb 23 10:39 AM
Robinson James GeorgeDirectorFeb 16Buy3.277,00022,9213,122,550Feb 20 04:20 PM
Robinson James GeorgeDirectorFeb 12Buy3.278,00026,1613,115,550Feb 13 09:45 AM
Robinson James GeorgeDirectorFeb 09Buy3.187,00022,2543,107,550Feb 12 11:00 AM
Robinson James GeorgeDirectorFeb 08Buy3.3710,00033,7173,100,550Feb 09 05:29 PM
Robinson James GeorgeDirectorFeb 02Buy3.475,00017,3503,090,550Feb 06 03:07 PM
Robinson James GeorgeDirectorJan 18Buy3.143,0009,4153,085,550Jan 22 03:19 PM
Robinson James GeorgeDirectorAug 03Buy3.675,00018,3503,082,550Aug 04 04:12 PM
Robinson James GeorgeDirectorAug 02Buy3.795,00018,9503,077,550Aug 04 04:12 PM
Robinson James GeorgeDirectorAug 01Buy3.675,00018,3503,072,550Aug 01 04:47 PM
Robinson James GeorgeDirectorJul 31Buy3.725,00018,6003,067,550Aug 01 04:47 PM
Robinson James GeorgeDirectorJul 28Buy3.775,00018,8503,062,550Aug 01 04:47 PM
Robinson James GeorgeDirectorJul 07Buy4.123,50014,4153,057,550Jul 07 04:34 PM
Robinson James GeorgeDirectorJul 06Buy3.923,00011,7703,054,050Jul 07 04:34 PM
Robinson James GeorgeDirectorJul 05Buy3.975,00019,8453,051,050Jul 07 04:34 PM
Robinson James GeorgeDirectorJun 28Buy4.013,50014,0503,046,050Jun 29 05:27 PM
Robinson James GeorgeDirectorJun 27Buy4.155,00020,7453,042,550Jun 29 05:27 PM
Robinson James GeorgeDirectorJun 26Buy4.005,00019,9753,037,550Jun 26 04:46 PM
Robinson James GeorgeDirectorJun 23Buy3.635,00018,1503,032,550Jun 26 04:46 PM
Robinson James GeorgeDirectorJun 22Buy3.775,00018,8503,027,550Jun 26 04:46 PM
Robinson James GeorgeDirectorJun 21Buy3.765,00018,8053,022,550Jun 21 04:49 PM
Robinson James GeorgeDirectorJun 20Buy3.765,00018,8173,017,550Jun 21 04:49 PM
Robinson James GeorgeDirectorJun 19Buy3.795,00018,9523,012,550Jun 21 04:49 PM
Robinson James GeorgeDirectorMay 30Buy3.8510,00038,5383,007,550May 31 01:31 PM
Robinson James GeorgeDirectorMay 26Buy3.784,50017,01049,550May 31 01:31 PM
Robinson James GeorgeDirectorMay 26Buy3.8140,000152,2122,997,550May 31 01:31 PM